Clay Siegall, the founder of Seattle Genetics, is a well-established powerhouse in the genetics field, specializing in targeted therapy for conditions with low mortality rates such as cancer. The company was founded in 1998 and has since partnered with big names such as Bayer and Genentech making most of their profit from licensing technologies that they have developed and production partners.
Clay holds a bachelors in zoology and earned his Ph.D. from George Washington University, and has since been a well-known figure throughout the medical world. He has worked with Bristol Meyers Squibb for over 7 years and has held multiple positions involving research and development throughout his career.
Throughout Clay Siegalls rewarding life, he has found time to author over 65 scientific papers and he holds over 6 patents. He has served on the Board of Governors of the Fred Hutchinson Cancer Research Business Alliance and as director of the Washington Biotechnology and Biomedical Association (WBBA).
A firm believer in keeping the backbone of Seattle Genetics standing straight, Clay appreciates the hard work and dedication his employees show for the company. He says that the drive to succeed takes a back seat to IQ and school choice and the smooth running of Seattle Genetics is the proof in that pudding.
“Targeted therapy medications are the future and chemotherapy will be left in the past as research expands”, he says. After witnessing a loved one suffer from current cancer treatments, Clay Siegall made a choice. He would build his career around targeted therapy and increase patients chance to live with a more survivable treatment plan and with over 20 years experience and a top-notch company with a solid and personable team of over 650 employees, Clay Siegall just might make that happen. Seattle Genetics is and will continue to be a strong contender as long as Clay Siegall continues to push for a cancer-free future.